PT - JOURNAL ARTICLE AU - Jafar Sarif AU - Deblina Raychaudhuri AU - Ranit D’Rozario AU - Purbita Bandopadhyay AU - Praveen Singh AU - Priyanka Mehta AU - Md. Asmaul Hoque AU - Bishnu Prasad Sinha AU - Manoj Kushwaha AU - Shweta Sahni AU - Priti Devi AU - Partha Chattopadhyay AU - Shekhar Ranjan Paul AU - Yogiraj Ray AU - Kausik Chaudhuri AU - Sayantan Banerjee AU - Debajyoti Majumdar AU - Bibhuti Saha AU - Biswanath Sharma Sarkar AU - Prasun Bhattacharya AU - Shilpak Chatterjee AU - Sandip Paul AU - Pramit Ghosh AU - Rajesh Pandey AU - Shantanu Sengupta AU - Dipyaman Ganguly TI - Plasma gradient of soluble urokinase-type plasminogen activator receptor is linked to pathogenic plasma proteome and immune transcriptome and stratifies outcomes in severe COVID-19 AID - 10.1101/2021.06.19.21259125 DP - 2021 Jan 01 TA - medRxiv PG - 2021.06.19.21259125 4099 - http://medrxiv.org/content/early/2021/06/21/2021.06.19.21259125.short 4100 - http://medrxiv.org/content/early/2021/06/21/2021.06.19.21259125.full AB - Disease caused by SARS-CoV-2 coronavirus (COVID-19) has resulted in significant morbidity and mortality world-wide. A systemic hyper-inflammation characterizes the severe COVID-19 disease often associated with acute respiratory distress syndrome (ARDS). Blood biomarkers capable of risk stratification are of great importance in effective triage and critical care of severe COVID-19 patients. In the present study we report higher plasma abundance of soluble urokinase-type plasminogen activator receptor (sUPAR), expressed by an abnormally expanded circulating myeloid cell population, in severe COVID-19 patients with ARDS. Plasma sUPAR level was found to be linked to a characteristic proteomic signature of plasma, linked to coagulation disorders and complement activation. Receiver operator characteristics curve analysis identified a cut-off value of sUPAR at 1996.809 pg/ml that could predict survival in our cohort (Odds ratio: 2.9286, 95% confidence interval 1.0427-8.2257). Lower sUPAR level than this threshold concentration was associated with a differential expression of the immune transcriptome as well as favourable clinical outcomes, both in terms of survival benefit (Hazard ratio: 0.3615, 95% confidence interval 0.1433-0.912) and faster disease remission in our patient cohort. Thus we identified sUPAR as a key pathogenic circulating molecule linking systemic hyperinflammation to the hypercoagulable state and stratifying clinical outcomes in severe COVID-19 patients with ARDS.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by grant no. MLP-129 from Council of Scientific and Industrial Research (CSIR), India, to D.G., who is also supported by a Swarnajayanti Fellowship grant from Department of Science & Technology, Government of India. The RNA-Seq was funded by the grants from CSIR (MLP-2005), Fondation Botnar (CLP-0031), IUSSTF (CLP-0033) and Intel (CLP-0034). J.S., R.D. and M.A.H. are supported by research fellowships from University Grants Commission, India. P.B. and P.S. are supported by Senior Research Fellowship from CSIR. P.M. and S.S. are supported by MLP-2005. P.D. and P.C. acknowledge CSIR for their Junior Research Fellowship.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All studies were done with due ethical approval from the institutional review boards of ID & BG Hospital, Kolkata, India (IDBGH/Ethics/2429) and CSIR-Indian Institute of Chemical Biology, Kolkata, India (IICB/IRB/2020/3P), in accordance with the Helsinki Declaration.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD026510. Detailed pathway enrichment data derived from the transcriptome analysis are depicted in supplemental table 4. Codes for reanalysis of the single cell RNA sequencing data are provided in supplemental information. All other data pertaining to the manuscript are available with the corresponding authors.